Ya.O. SHEVNINA², M.A. AFANASYEVA^1,2, S.A. LAPSHINA^1,2, E.V. SUKHORUKOVA¹, R.Z. ABDRAKIPOV¹, T.Yu. NURIAKHMETOVA², N.L. NOVICHKOVA², D.I. ABDULGANIYEVA^1,2

¹Republic Clinical Hospital of the MH of RT, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064

²Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Shevnina Ya.O. ― resident doctor of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: janashevnina1@gmail.com

Afanasyeva M.A. ― doctor of the Rheumatology Department, tel. (843) 231-21-67, e-mail: afmaria2108@mail.ru

Lapshina S.A. ― Cand. Med. Sc., Assistant of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: svetlanalapshina@mail.ru

Sukhorukova E.V. — doctor of the Rheumatology Department, tel. (843) 231-21-67, e-mail: s-elena1407@mail.ru

Abdrakipov R.Z. ― Head of the Rheumatology Department, tel. (843) 231-21-67, e-mail: hosptherapy@mail.ru

Nuriakhmetova T.Yu. ― postgraduate student of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: tatiana.afanaseva.ksmu@gmail.com

Novichkova N.L. ― resident doctor of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: novichkovanl@yandex.ru

Abdulganiyeva D.I. ― D. Med. Sc., Professor, Head of the Department of Hospital Therapy, tel. (843) 237-34-83, e-mail: diana_s@mail.ru

The article presents a literature review of ankylosing spondylitis treatment. Also the results are presented of along-term dynamic observation of 9 patients with reliable diagnosis of ankylosing spondylitis (AS) with high activity according to ASDAS/BASDAI and MRI-verified sacroiliitis with peripheral arthritis. The patients received methotrexate as the main anti-inflammatory medication for a long period of time, from 1 to 6 years. Evaluation of the results was performed 6 months after starting the treatment with methotrexate and by the end of the 1^st year of treatment. Positive clinical effect, reduction of disease laboratory activity and improvement of the patients’ functional capacity was noted in the course of the treatment. The article also contains the description of a clinical case of one of the observed patients with low disease activity achieved on methotrexate treatment and supporting glucocorticoid doses. Long-term methotrexate treatment allows achieving good results and may be considered as an alternative of treatment of AS combined with peripheral arthritis.

Key words: ankylosing spondylitis, methotrexate use in ankylosing spondylitis combined with peripheral arthritis.

 REFERENCES

1. Revmatologiya. Natsional’noe rukovodstvo, pod red. akad. RAMN E.L. Nasonova, akad. RAMN V.A. Nasonovoy [Rheumatology. National leadership. Under the editorship of academicians RAMS E.L. Nasonov and V.A. Nasonova]. Moscow, 2010. 13. P. 332.
2. Erdes Sh.F., Badokin V.V., Bochkova A.G. et al. On the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya, 2015, 53 (6), pp. 657-660 (in Russ.).
3. Klinicheskie rekomendatsii po diagnostike i lecheniyu ankiloziruyushchego spondilita (bolezn’ Bekhtereva). Obshcherossiyskaya obshchestvennaya organizatsiya [Clinical recommendations for the diagnosis and treatment of ankylosing spondylitis (Bekhterev’s disease). All-Russian public organization]. Moscow, 2013.
4. Sieper J., Poddubnyy D. New evidence on the management of spondyloarthritis. Nat. Rev. Rheumatol, 2016, May, 12 (5), pp. 282-95.
5. Kroon F.P., Van der Burg L.R., Ramiro S. et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst. Rev, 2015, Jul 17.
6. Boersmaj W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazon. Scand. J. Rheumatol, 1976, 5, pp. 60-4.
7. Wanders A., Van der Heijde D., Landewe R. et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum, 2005, 52, pp. 1756-65.
8. Bochkova A.G. Features of the use of nonsteroidal anti-inflammatory drugs in spondyloarthritis. Consilium Medicum, 2010, 12 (9), pp. 13-18 (in Russ.).
9. Dougados M., Dijrmans B., Khan M. et al. Sonventional treatments for ankylosingspondylitis. Ann. Rheum. Dis, 2002, 61 (Suppl III), pp. 40-50.
10. Lapshina S.A., Dubinina T.V., Badokin V.V. et al. Inhibitors of tumor necrosis factor α in the treatment of axial spondylitis (including ankylosing spondylitis). Nauchno-prakticheskaya revmatologiya revmatologiya, 2016, 54 (appl. 1), pp. 75-79 (in Russ.).
11. Arends S., Lebbink H.R., Spoorenberg A., et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin. Exp. Rheumatol., 2010 Sep-Oct, 28 (5), pp. 661-8. Epub 2010 Oct 22.
12. Murdaca G., Spanò F., Contatore M., et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin. Drug. Saf, 2016, Jan, 15 (1), pp. 43-52.
13. Chen J., Lin S., Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Data base Syst. Rev, 2014, Nov 27.
14. Erdes Sh.F. Basic principles of therapy of ankylosing spondylitis (Bekhterev’s disease). Nauchno-prakticheskaya revmatologiya, 2013, no. 6, pp. 686-695 (in Russ.).
15. Clegg D.O., Reda D.J., Blackburn W.D. Comparison of sulphasalazine and placebo in the treatment of AS. A department of veterans affairs cooperative study. Arthr. Rheum, 1996, 39, 12, pp. 2004-2012.
16. Clegg L.J., Reda D.J., Abdellatif M. Comparison of sulphasalazine for the treatment and placebo of axial and peripher-iai articular manifestations of the seronegative spondyloarthropathies. Arthr. Rheum, 1999, 42, pp. 2325-2329.
17. Davis M.J., Dawes P.T., Beswick E., Lewin I.V., Stranworth D.R. Sulphasalazine therapy in AS. Br. J. Rheum, 1989, 28, pp. 410-413.
18. Chepeleva C.N., Sigidin Ya.A., Lukina G.V. A controlled evaluation of the efficacy of sulfasalazine in ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya, 2001, no. 4, pp. 32-37.
19. Orlov-Morozov A.V. An exacerbation of ankylosing spondylitis with an attempt to treat small doses of methotrexate. Al’manakh klinicheskoy meditsiny, 2014, 35, pp. 77-8 (in Russ.).
20. Can M., Aydkhn S.Z., Nigdelioglu A. et al. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing.
21. Chen J., Veras M.M., Liu C., Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev., 2013 Feb 28.
22. Altan L. et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol, 2001, 30, pp. 255-9.
23. Wanders A., Heijde Dv., Landewé R., et al. Nonsteroid alantiin flammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum, 2005, Jun, 52 (6), pp. 1756-65.
24. Federal’nye klinicheskie rekomendatsii po revmatoidnomu artritu. Obshcherossiyskaya obshchestvennaya organizatsiya [Federal clinical guidelines for rheumatoid arthritis. All-Russian public organization]. Moscow, 2013.
25. MCW Creemers et al. Methotrexate in Severe Ankylosing Spondylitis: An Open Study. J. Rhematol, 1995, 22, pp. 1104-7.
26. Roychowdhury B. et al. Is methotrexate effective in ankylosing spondylitis?. Rheumatology (Oxford), 2002, 41 (11), pp. 1330-2.
27. Samhaio-Barros P.D., Costallat L.T.L., Bertolo M.B. et al. Methotrekhate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol, 200, 29, pp. 160-2.